Objective. To assess the cost implications to payers of improving @entity413 management among adults with type 2 @entity6 . Data Source/Study Setting. Medical-record data from the Community Quality Index (CQI) study (1996-2002), pharmaceutical claims from four Massachusetts health plans (2004-2006), Medicare Fee Schedule (2009), published literature. Study Design. Probability tree depicting @entity413 management over 1 year. Data Collection/Extraction Methods. We determined how frequently CQI study subjects received recommended care processes and attained @entity283 ( @entity283 ) treatment goals, estimated utilization of visits and medications associated with recommended care, assigned costs based on utilization, and then modeled how hospitalization rates, costs, and goal attainment would change if all recommended care was provided. Principal Findings. Relative to current care, improved @entity413 management would cost U.S. 327 (U.S. 192-711 in sensitivity analyses) more per @entity1 with @entity6 annually, largely due to antihyperglycemic medications. Cost-effectiveness to payers, defined as incremental annual cost per @entity1 newly attaining any one of three @entity283 goals, would be U.S. 1,128; including glycemic crises reduces this to U.S. 555-1,021. Conclusions. The cost of improving @entity413 management appears modest relative to @entity6 -related health care expenditures. The incremental cost per @entity1 newly attaining @entity283 goals enables payers to consider costs as well as outcomes that are linked to future profitability.

Cost implications to health care payers of improving @entity413 management among adults with type 2 XXXX .

@entity1 :: ('9606', 'Species') :: ['patient', 'person'] @entity283 :: ('OMIM:603663', 'Disease') :: ['Health Care Effectiveness Data and Information Set', 'HEDIS'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
